Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TAK-280 by Takeda Pharmaceutical for Metastatic Uveal Melanoma: Likelihood of Approval
TAK-280 is under clinical development by Takeda Pharmaceutical and currently in Phase II for Metastatic Uveal Melanoma. According to GlobalData,...
TAK-280 by Takeda Pharmaceutical for Small-Cell Lung Cancer: Likelihood of Approval
TAK-280 is under clinical development by Takeda Pharmaceutical and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...
TAK-280 by Takeda Pharmaceutical for Non-Small Cell Lung Cancer: Likelihood of Approval
TAK-280 is under clinical development by Takeda Pharmaceutical and currently in Phase II for Non-Small Cell Lung Cancer. According to...